☆ 4.5 Article

Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer

LUNG CANCER (2012)

期刊

LUNG CANCER

卷 77, 期 1, 页码 89-96

出版社

ELSEVIER IRELAND LTD

DOI: 10.1016/j.lungcan.2012.02.011

关键词

NSCLC; Locally advanced; Concurrent chemoradiation; Cisplatin; Etoposide; Paclitaxel; Carboplatin

类别

Oncology Respiratory System

资金

CSCO Foundation [Y-20040007]
National 115 Project: Multimodality treatment for lung cancer [2006BAI02A02 [1]-03]

向作者/读者索取更多资源

Protocol

Reagent

摘要

Objective: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). Patients and methods: Patients were randomly assigned to receive the following treatments: PE arm, cisplatin (50 mg/m(2)) on days 1, 8, 29, and 36 and etoposide (50 mg/m(2)) on days 1-5 and 29-33 plus 60 Gy of TRT; PC arm, weekly concurrent carboplatin (AUC = 2) and paclitaxel (45 mg/m2) plus 60 Gy of TRT. Results:A total of 65 patients were randomized (PE arm, n = 33; PC arm, n = 32). The 3-year overall survival (OS) was significantly better in the PE arm than in the PC arm (33.1% vs. 13%, P = .04). The incidence of Grade 3/4 neutropenia was 78.1% in the PE arm and 51.5% in the PC arm (P = .05). The rate of Grade 2 or greater radiation pneumonitis was 25% in the PE arm and 48.5% in the PC arm (P = .09). Conclusions: Compared to PE regimen, weekly PC regimen cannot be recommended since it failed to achieve an improvement in either OS or PFS. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study

Ursula A. Matulonis, Helen Q. Huang, Virginia L. Filiaci, Marcus Randall, Paul A. DiSilvestro, Katherine M. Moxley, Jeffrey M. Fowler, Matthew A. Powell, Nick M. Spirtos, Krishnansu S. Tewari, William E. Richards, John M. Nakayama, David G. Mutch, David S. Miller, Daniela Matei, Lari B. Wenzel

Summary: Chemotherapy plus radiation did not show superiority over chemotherapy alone in treating stage III or IVA endometrial carcinoma. Although the combined treatment led to a decline in quality of life and gastrointestinal toxicity, these differences were not clinically meaningful.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Otorhinolaryngology

Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer

James Han, Kaveh Zakeri, Gabriel Raab, Jennifer Hesse, Achraf Shamseddine, Linda Chen, Yao Yu, Jung Julie Kang, Sean M. M. McBride, Nadeem Riaz, C. Jillian Tsai, Daphna Gelblum, Eric J. J. Sherman, Richard J. J. Wong, Loren Michel, Nancy Y. Y. Lee

Summary: This study reports the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation using carboplatin and paclitaxel. The results show that chemoradiation with carboplatin and paclitaxel is an effective treatment option for controlling locoregional recurrences and distant metastases, and improving progression-free survival and overall survival in these patients.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2023)

添加到收藏夹

Article Oncology

Comparative analyses of paclitaxel/carboplatin with cisplatin/5-fluorouracil-based chemoradiation in locally advanced inoperable upper and middle third esophageal cancer: A randomized prospective pilot study

Divyesh Kumar, Treshita Dey, Divya Khosla, Sandeep Gedela, Arun S. Oinam, Rakesh Kapoor

Summary: This pilot study compares the treatment outcomes, survival, and toxicities of two different chemoradiation therapy regimens in inoperable upper and middle third esophageal cancer patients. The results suggest that paclitaxel/carboplatin therapy shows better response and survival rates compared to cisplatin/5FU therapy, although the difference is not statistically significant.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer A Randomized Clinical Trial

Dashan Ai, Jinjun Ye, Shihong Wei, Yunhai Li, Hui Luo, Jianzhong Cao, Zhengfei Zhu, Weixin Zhao, Qin Lin, Huanjun Yang, Xiangpeng Zheng, Jialiang Zhou, Guang Huang, Ling Li, Jiancheng Li, Zhi Zhang, Guoren Zhou, Dayong Gu, Mingyu Du, Miao Mo, HuiXun Jia, Zhen Zhang, Kuaile Zhao

Summary: This randomized clinical trial compared the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma (ESCC). The results showed that paclitaxel plus fluorouracil did not have superior overall survival compared to paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in locally advanced ESCC. The cisplatin group had higher rates of hematologic and gastrointestinal toxic effects.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Health Care Sciences & Services

First Results of Concurrent Chemoradiation with Two Courses of 5 x 25 mg/m2 Cisplatin for Locally Advanced Head and Neck Cancer

Inga Zwaan, Tamer Soror, Christian Idel, Ralph Pries, Karl L. Bruchhage, Samer G. Hakim, Nathan Y. Yu, Dirk Rades

Summary: In patients with squamous cell carcinoma of the head and neck, cisplatin-based chemoradiation is commonly used. This study compared two different cisplatin regimens and found that a dose of 250 mg/m2 over five days appeared to be more effective in controlling local and distant spread, while overall survival was similar to a dose of 200 mg/m2. However, longer follow-up and a larger sample size are needed to further validate these findings.

JOURNAL OF PERSONALIZED MEDICINE (2023)

添加到收藏夹

Article Oncology

High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial

Hyo Chun Lee, Jae Won Jeong, Joo Hwan Lee, Sung Hwan Kim, Dong Chun Park, Joo Hee Yoon, Sang Il Kim, Jong Hoon Lee

Summary: Radiotherapy dose-escalation using IMRT is necessary for improving treatment outcomes in cervical cancer. This study showed that high-dose IMRT with concurrent weekly cisplatin resulted in favorable progression-free survival outcomes.

GYNECOLOGIC ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study

Xing Gao, Ping-Chung Tsai, Kai-Hao Chuang, Chu-Pin Pai, Po-Kuei Hsu, Shau-Hsuan Li, Hung- Lu, Joseph Jan-Baptist van Lanschot, Yin-Kai Chao

Summary: This study compared the efficacy of two commonly used neoadjuvant chemoradiotherapy regimens and found that the CROSS regimen resulted in lower treatment-related complications and better survival outcomes for Taiwanese patients with esophageal squamous cell carcinoma. These results are important for guiding treatment decisions for patients with this type of cancer in Asian populations.

CANCERS (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study

Li Jiang, Jie Zhu, Xue Chen, Yi Wang, Lei Wu, Gang Wan, Yongtao Han, Xuefeng Leng, Lin Peng, Qifeng Wang

Summary: This study evaluated the efficacy and safety of different chemotherapy regimens in patients with locally advanced esophageal squamous cell carcinoma who underwent neoadjuvant chemoradiotherapy. The results showed that there was no significant difference in overall survival and progression-free survival between the paclitaxel plus cisplatin (TP) and carboplatin (TC) groups. However, the TP group had a higher incidence of adverse events, including febrile neutropenia.

RADIATION ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Early GLS changes detection after chemoradiation in locally advanced non-small cell lung cancer (NSCLC)

Simona Mega, Michele Fiore, Myriam Carpenito, Maria Laura Novembre, Marianna Miele, Luca Eolo Trodella, Francesco Grigioni, Edy Ippolito, Sara Ramella

Summary: This study evaluates early changes in cardiac function after chemoradiotherapy in patients with non-small-cell lung cancer. The results indicate that global longitudinal strain and ejection fraction progressively decrease after treatment, with a significant correlation. Additionally, some patients experience cardiac arrhythmias after treatment.

RADIOLOGIA MEDICA (2022)

添加到收藏夹

Article Oncology

Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma

Hui Jiang, Qiaoqiao Li, Baoqing Chen, Mian Xi, Kanjiebubi Makelike, Shiliang Liu, Yonghong Hu, Yujia Zhu

Summary: This study aimed to evaluate the safety, dose-limiting toxicity, maximum tolerated dose, and preliminary effect of nanoparticle albumin-bound paclitaxel in combination with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The results showed that this treatment regimen was effective and well-tolerated for patients with locally advanced esophageal squamous cell carcinoma.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar

Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin

Nandini S. Menon, Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Atanu Bhattacharjee, Devanshi Kalra, Sarbani Ghosh Laskar, Vijayalakshmi Mathrudev, Kavita Nawale, Arati S. Bhelekar, Kumar Prabhash

Summary: This study found that the use of once-every-3-weeks cisplatin with radiation did not have a negative impact on the quality of life for patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC), compared to once-a-week cisplatin. However, there were significant differences in the scales of constipation, reduced sexuality, and financial difficulty between the two treatment arms.

CANCER MEDICINE (2022)

添加到收藏夹

Article Oncology

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

Christian Wilhelm Langberg, Henrik Horndalsveen, Aslaug Helland, Vilde Drageset Haakensen

Summary: This study identifies factors associated with failure to start consolidation immunotherapy after chemoradiotherapy in patients with non-small cell lung cancer. Results show that patients with higher lactate dehydrogenase, worse performance status, cumulative toxicity, and higher c-reactive protein are less likely to start immunotherapy. Further research and prospective trials are needed to investigate the potential of prehabilitation and supportive treatment in optimizing treatment outcomes.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Wenwu He, Xuefeng Leng, Tianqin Mao, Xi Luo, Lingxiao Zhou, Jiaxin Yan, Lin Peng, Qiang Fang, Guangyuan Liu, Xing Wei, Kangning Wang, Chenghao Wang, Sha Zhang, Xudong Zhang, Xudong Shen, Depei Huang, Huan Yi, Ting Bei, Xueke She, Wenguang Xiao, Yongtao Han

Summary: This study focuses on locally advanced resectable esophageal squamous cell carcinoma (ESCC), investigating the safety, feasibility, and efficacy of neoadjuvant toripalimab plus paclitaxel and carboplatin treatment. The results indicate that this combination therapy shows potential as a neoadjuvant treatment for ESCC, with increased CD8(+) T cells and decreased M2-type tumor-associated macrophages in responders. Furthermore, certain molecular signatures were associated with treatment response.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer

Neal S. McCall, James R. Janopaul-Naylor, H. Scott McGinnis, Aparna H. Kesarwala, Sibo Tian, William A. Stokes, Joseph W. Shelton, Conor E. Steuer, Jennifer W. Carlisle, Ticiana A. Leal, Suresh S. Ramalingam, Jeffrey D. Bradley, Kristin A. Higgins

Summary: This study aimed to evaluate the efficacy and tolerability of durvalumab in Black and non-Black patients after concurrent chemoradiation. The results showed no significant differences in overall survival, progression-free survival, and ≥3 grade pneumonitis-free survival between Black and non-Black patients.

CANCER (2023)

添加到收藏夹

暂无数据

暂无数据

© Peeref 2019-2024. All rights reserved.